[1]WANG Y J. Residual recurrence risk of ischaemic cerebrovascular events：concept，classification and implications[J]. Stroke Vasc Neurol，2021，6（2）：155-157.
[2]WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[3]JOHNSTON S C，EASTON J D，FARRANT M，et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med，2018，379（3）：215-225.
[4]JOHNSTON S C，AMARENCO P，DENISON H，et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med，2020，383（3）：207-217.
[5]JOH NSTON S C，AMARENCO P，ALBERS G W，et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack[J]. N Engl J Med，2016，375（1）：35-43.
[6]BATH P M，WOODHOUSE L J，APPLETON J P，et al. Antiplatelet therapy with aspirin，clopidogrel，and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia（TARDIS）：a randomised, open-label，phase 3 superiority trial[J]. Lancet，2018，391（10123）：850-859.
[7]WANG Y L，LIN X，MENG X，et al. Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack（PRINCE）trial：rationale and design[J]. Int J Stroke，2017，12（3）：321-325.
[8]WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021. 385（27）：2520-2530.
